In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme acquires rights to three drugs from Bayer HealthCare

Executive Summary

In an agreement funded solely through the achievement of milestones and royalties, Bayer HealthCare has licensed Genzyme exclusive global development and commercialization rights to Campath/MabCampath (alemtuzumab) for multiple sclerosis and B-cell chronic lymphocytic leukemia (CLL), and exclusive worldwide rights to present and future indications of the cancer drugs Fludara (fludarabine) and Leukine (sargramostim).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies